RxDoctor Payments Data

Bernard Ashby, MD

Cardiovascular Disease · Miami, FLNPI 1679732622

Payments from drug & device makers

$469,461in general payments, 2019–2025

Across 223 payments — averaging $2105.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$162K
  • Paratek Pharmaceuticals, Inc.$108K
  • GSK$64K
  • Novo Nordisk$63K
  • AbbVie$39K
  • American Regent$21K
  • plus $12K from 20 others
$247,653in research payments, 2019–2025

Across 245 payments — averaging $1010.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vifor (international) Ltd.$237K
  • AbbVie$8K
  • GSK$1K
  • Sanofi US Services Inc.$993

What the payments were for

  • Consulting fees$43,79538%
  • Speaking & faculty fees$54,72448%
  • Travel & lodging$12,28111%
  • Food & beverage$3,7903%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$469,461 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$29,380
Medicare patients
27
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$67,179
EntrestoSacubitril/Valsartan64$64,487
MounjaroTirzepatide14$21,170
EliquisApixaban18$20,926
FarxigaDapagliflozin Propanediol20$18,931
XareltoRivaroxaban19$18,770
Nifedipine ErNifedipine19$1,270
Rosuvastatin Calcium60$865
Metoprolol Succinate21$580
ClopidogrelClopidogrel Bisulfate50$391
Atenolol34$235
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide11$231
Carvedilol28$157
Metformin Hcl14$157
Sildenafil Citrate13$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62,609$67,17961 claims
Lilly USA, LLCMounjaro$13$21,17014 claims
PfizerEliquis$1,516$20,92618 claims
AstraZenecaFarxiga$159$18,93120 claims
Johnson & JohnsonXarelto$408$18,77019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →